Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10140731 | 0.80 | KMT2A (0.30) | KMT2A | |
| SCHEMBL18769017 | 0.80 | CASP2 (0.42) | CASP2TSHRMEN1KMT2ANAAA | |
| SCHEMBL23127562 | 0.80 | CASP2 (0.42) | CASP2TSHRMEN1KMT2ANAAA | |
| SCHEMBL20224684 | 0.80 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL18588478 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CASP2TSHRNAAA | |
| SCHEMBL13852384 | 0.77 | POLB (0.40) | ALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL18866882 | 0.77 | CASP2 (0.53) | ALDH1A1CASP2SMN1; SMN2NAAA | |
| SCHEMBL20794399 | 0.77 | GAA (0.46) | ALDH1A1MEN1MAPTKMT2ANAAA | |
| SCHEMBL29329063 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CASP2TSHRMEN1MAPT | |
| SCHEMBL16248535 | 0.76 | ALDH1A1 (0.53) | ALDH1A1CASP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | ALDH1A1 2941/4885CASP2 1421/4885TSHR 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.